Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 75-85

  Bajetta, Emilio ^a   Del Vecchio, Michele ^a   Mortarini, Roberta ^a   Nadeau, Rosemary ^c   Rakhit, Ashok ^c   Rimassa, Lorenza ^a   Fowst, Camilla ^b   Borri, Alessandra ^a   Anichini, Andrea ^a   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ROCHE MILANO RICERCHE   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 12;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MELANOMA; METASTASIS; NEUTROPENIA; PHARMACODYNAMICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; CYTOKINES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-12; LEUKOCYTES; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT PROTEINS;

EID: 0031929620     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Rigel, D. S., Friedman, R. J., and Kopf, A. W. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatol., 34: 839-847, 1996.
2. Franceschi, S., La Vecchia, C., Lucchini, F., and Cristofolini, M. The epidemiology of cutaneous malignant melanoma: aetiology and European data. Eur. J. Cancer Prev., 1: 9-22, 1991.
3. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol., 14: 7-17, 1996.
4. Bajetta, E., Di Leo, A., Zampino, M. G., Sertoli, M. R., Comella, G., Barduagni, M., Giannotti, B., Queirolo, P., Tribbia, G., Bernengo, M. G., Menichetti, E. T., Palmeri, S., Russo, A., Cristofolini, M., Erbazzi, A., Fowst, C., Criscuolo, D., Bufalino, R., Zilembo, N., and Cascinelli, N. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J. Clin. Oncol., 12: 806-811, 1994.
5. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.
6. Cole, B. F., Gelber, R. D., Kirkwood, J. M., Goldhirsch, A., Barylak, E., and Borden, E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol., 14: 2666-2673, 1996.
7. Bear, H. D., Hamad, G. G., and Kostuchenko, P. J. Biologic therapy of melanoma with cytokines and lymphocytes. Semin. Surg. Oncol., 12: 436-445, 1996.
8. Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst., 86: 1159-1166, 1994.
9. Van Pel, A., van der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethe, B., van den Eynde, B., Uyttenhove, C., Renauld, J. C., and Boon, T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev., 145: 229-250, 1995.
10. Sensi, M., and Parmiani, G. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol. Today, 16: 588-595, 1995.
11. Scott, P. IL-12: initiation cytokine for cell-mediated immunity. Science (Washington DC), 260: 496-497, 1993.
12. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994.
13. Takeda, K., Seki, S., Ogasawara, K., Anzai, R., Hashimoto, W., Sugiura, K., Takahashi, M., Satoh, M., and Kumagai, K. Liver NK1.1 + CD4+ α β T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J. Immunol., 156: 3366-3373, 1996.
14. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
15. Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C., and Stoppacciaro, A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res., 56: 2531-2534, 1996.
16. Zitvogel, L., Robbins, P. D., Storkus, W. J., Clarke, M. R., Maeurer, M. J., Campbell, R. L., Davis, C. G., Tahara, H., Schreiber, R. D., and Lotze, M. T. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol., 26: 1335-1341, 1996.
17. Rodolfo, M., Zilocchi, C., Melani, C., Cappetti, B., Arioli, I., Parmiani, G., and Colombo, M. P. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol., 157: 5536-5542, 1996.
18. Zou, J. P., Yamamoto, N., Fujii, T., Takenaka, H., Kobayashi, M., Herrmann, S. H., Wolf, S. F., Fujiwara, H., and Hamaoka, T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol., 7: 1135-1145, 1995.
19. Claffey, K. P., Brown, L. F., del Aguila, L. F., Tognazzi, K., Yeo, K. T., Manseau, E. J., and Dvorak, H. F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis and experimental metastasis. Cancer Res., 56: 172-181, 1996.
20. Czubayko, F., Schulte, A. M., Berchem, G. J., and Wellstein, A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc. Natl. Acad. Sci. USA, 93: 14753-14758, 1996.
21. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. Inhibition of angiogenesis in vivo by interleukin 12. J. Nat. Cancer Inst., 87: 581-586, 1995.
22. Majewski, S., Marczak, M., Szmurlo, A., Jablonska, S., and Bollag, W. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J. Invest. Dermatol., 106: 1114-1118, 1996.
23. Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., and Tosato, G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 182: 155-162, 1995.
24. Yu, W. G., Yamamoto, N., Takenaka, H., Mu, J., Tai, X. G., Zou, J. P., Ogawa, M., Tsutsui, T., Wijesuriya, R., Yoshida, R., Herrmann, S., Fujiwara, H., and Hamaoka, T. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int. Immunol., 8: 855-865, 1996.
25. Appendix A. Grading of toxicity. In: R. E. Wittes (ed.), Manual of Oncologic Therapeutics, pp. 445-448. Philadelphia: J. B. Lippincott, 1991.
26. Sarmiento, U. M., Riley, J. H., Knaack, P. A., Lipman, J. M., Becker, J. M., Gately, M. K., Chizzonite, R., and Anderson, T. D. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest., 71: 862-873, 1994.
27. Vadhan-Raj, S., Al-Katib, A., Bhalla, R., Pelus, L., Nathan, C. F., Sherwin, S. A., Oettgen, H. F., and Krown, S. E. Phase I trial of recombinant interferon γ in cancer patients. J. Clin. Oncol., 4: 137-146, 1986.
28. Perez, R., Lipton, A., Harvey, H. A., Simmonds, M. A., Romano, P. J., Imboden, S. L., Giudice, G., Downing, M. R., and Alton, N. K. A Phase I trial of recombinant human γ interferon (IFN-γ 4A) in patients with advanced malignancy. J. Biol. Response Modif., 7: 309-317, 1988.
29. Desai, B. B., Quinn, P. M., Wolitzky, A. G., Mongini, P. K., Chizzonite, R., and Gately, M. K. IL-12 receptor. II. Distribution and regulation of receptor expression. J. Immunol., 148: 3125-3132, 1992.
30. Presky, D. H., Yang, H., Minetti, L. J., Chua, A. O., Nabavi, N., Wu, C. Y., Gately, M. K., and Gubler, U. A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits. Proc. Natl. Acad. Sci. U. S. A., 93: 14002-14007, 1996.
31. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., and Sherman, M. L. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin. Cancer Res., 3: 409-417, 1997.
32. Allavena, P., Paganin, C., Zhou, D., Bianchi, G., Sozzani, S., and Mantovani, A. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood, 84: 2261-2268, 1994.
33. Taub, D. D., Lloyd, A. R., Conlon, K., Wang, J. M., Ortaldo, J. R., Harada, A., Matsushima, K., Kelvin, D. J., and Oppenheim, J. J. Recombinant human interferon inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med., 177: 1809-1814, 1993.
34. Taub, D. D., Longo, D. L., and Murphy, W. J. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood, 87: 1423-1431, 1996.
35. Bukowski, R. M., Rayman, P., Olencki, T., Peereboom, D., Andresen, S., Budd, G. T., Sandstrom, K., McLain, D., Don, W., Tinetti, A., Griffin, T., and Finke, J. Interleukin-12 (IL-12) administration to patients with renal cell carcinoma: effects on cytokine gene expression in peripheral blood, skin and tumor. Proc. Am. Soc. Clin. Oncol., 15: 354, 1996.
36. Vora, M., Romero, L. I., and Karasek, M. A. Interleukin-10 induces E-selectin on small and large blood vessel endothelial cells. J. Exp. Med., 184: 821-829, 1996.
37. Kansas, G. S. Selectins and their ligands: current concepts and controversies. Blood, 88: 3259-3287, 1996.
38. Lee, K. H., Chung, K. Y., and Koh, Y. J. Memory T lymphocytes' adherence to interferon γ-activated human dermal microvascular endothelial cells via E-selectin. J. Dermatol. Sci., 10: 166-175, 1995.
39. Cartwright, J. E., Whitley, G. S., and Johnstone, A. P. The expression and release of adhesion molecules by human endothelial cell lines and their consequent binding of lymphocytes. Exp. Cell. Res., 217: 329-335, 1995.
40. Gately, M. K., Warner, R. R., Honasoge, S., Carvajal, D. M., Faherty, D. A., Connaughton, S. E., Anderson, T. D., Sarmiento, U., Hubbard, B. R., and Murphy, M. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol., 6: 157-167, 1994.
41. Windhagen, A., Anderson, D. E., Carrizosa, A., Williams, R. E., and Hafler, D. A. IL-12 induces human T cells secreting IL-10 with IFN-γ. J. Immunol., 157: 1127-1131, 1996.
42. Gerosa, F., Paganin, C., Peritt, D., Paiola, F., Scupoli, M. T., Aste-Amezaga, M., Frank, I., and Trinchieri, G. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-γ and interleukin-10. J. Exp. Med., 183: 2559-2569, 1996.
43. Meyaard, L., Hovenkamp, E., Otto, S. A., and Miedema, F. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J. Immunol., 156: 2776-2782, 1996.
44. Moore, K. W., O'Garra, A., de Waal Malefyt, R., Vieira, P., and Mosmann, T. R. Interleukin 10. Annu. Rev. Immunol., 11: 165-190, 1993.
45. Berman, R. M., Suzuki, T., Tahara, H., Robbins, P. D., Narula, S. K., and Lotze, M. T. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J. Immunol., 157: 231-238, 1996.
46. Zheng, L. M., Ojcius, D. M., Garaud, F., Roth, C., Maxwell, E., Li, Z., Rong, H., Chen, J., Wang, X. Y., Catino, J. J., and King, I. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med., 184: 579-584, 1996.
47. Groux, H., Bigler, M., de Vries, J. E., and Roncarolo, M. G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med., 184: 19-29, 1996.
48. Mu, J., Zou, J. P., Yamamoto, N., Tsutsui, T., Tai, X. G., Kobayashi, M., Herrmann, S., Fujiwara, H., and Hamaoka, T. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res., 55: 4404-4408, 1995.
49. Verbik, D. J., Stinson, W. W., Brunda, M. J., Kessinger, A., and Joshi, S. S. In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin. Exp. Metastasis, 14: 219-229, 1996.